Drug Trial Radar · NCT03589469
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Aug 1, 2018
Primary completion
May 24, 2020
Study completion Aug 9, 2022
Sponsor
- Lead sponsor
- ADC Therapeutics S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
Conditions
- Diffuse Large B-Cell Lymphoma Refractory
- Diffuse Large B-cell Lymphoma Recurrent
Interventions
Loncastuximab tesirineDrug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 21.5 months
Locations
37 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
Compassionate Care Research Group, Inc., at Compassionate Care Medical Group, Inc.
Fountain Valley, California
UC San Diego Moores Cancer Center
La Jolla, California
University of California, San Francisco Medical Center
San Francisco, California
The Oncology Institute of Hope and Innovation
Whittier, California
University of Miami Hospital and Clinics
Miami, Florida
Miami Cancer Institute
Miami, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Northwest Georgia Oncology Centers, PC-Drug Shipment, Lab and Study Supplies Only
Marietta, Georgia
Medical Oncology & Hematology Associates
Des Moines, Iowa
Ochsner Clinic Foundation
New Orleans, Louisiana
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center/ Nebraska Medicine
Omaha, Nebraska
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists
East Setauket, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania
Hollings Cancer Center
Charleston, South Carolina
GHD Cancer Institute
Greenville, South Carolina
Baylor University Medical Center
Dallas, Texas
Baylor Scott & White Medical Center - Temple
Temple, Texas
Virginia Cancer Specialists, PC
Fairfax, Virginia
Vista Oncology Inc. PS
Olympia, Washington
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin
Dipartimento di Oncomatlolgia - Unita Linfomi
Milan, Italy
Divisione di Oncoematologia
Milan, Italy
A.O. SS Antonio e Biagio e Cesare Arrigo
Alessandria, AL, Italy
Istituto di Ematologia Seragnoli
Bologna, BO, Italy
U.O. Oncologia ed Ematologia
Rozzano, Milano, Italy
Anastasios Stathis
Bellinzona, Canton Ticino, Switzerland
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
University Hospitals of Leicester NHS Trust.
Leicester, England, United Kingdom
University College London Hospital
London, England, United Kingdom
The Christie NHS Foundation Trust
Manchester, England, United Kingdom
Oxford Cancer Centre, Churchill Hospital
Oxford, England, United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, Scotland, United Kingdom
Abertawe Bro Morgannwg University Health Board - Singleton Hospital
Swansea, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.